MCID: RRT020
MIFTS: 43

Rare Tumor

Categories: Cancer diseases, Eye diseases, Rare diseases

Aliases & Classifications for Rare Tumor

MalaCards integrated aliases for Rare Tumor:

Name: Rare Tumor 59
Rare Neoplasm 59

Classifications:



External Ids:

UMLS via Orphanet 73 C0375111
Orphanet 59 ORPHA98057

Summaries for Rare Tumor

MalaCards based summary : Rare Tumor, also known as rare neoplasm, is related to desmoplastic small round cell tumor and dermatofibrosarcoma protuberans. An important gene associated with Rare Tumor is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Cytoskeletal Signaling. The drugs leucovorin and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include breast, pancreas and liver, and related phenotypes are homeostasis/metabolism and immune system

Related Diseases for Rare Tumor

Diseases in the Rare Tumor family:

Rare Eye Tumor

Diseases related to Rare Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 661)
# Related Disease Score Top Affiliating Genes
1 desmoplastic small round cell tumor 32.0 EWSR1 DES
2 dermatofibrosarcoma protuberans 31.9 KIT DES ACTC1
3 rhabdomyosarcoma 30.5 EWSR1 DES ACTC1
4 mesenchymal cell neoplasm 30.5 KIT EWSR1
5 leiomyosarcoma 30.5 KIT DES ACTC1
6 fibrous histiocytoma 30.3 EWSR1 DES ACTC1
7 ewing's family of tumors 30.3 KIT EWSR1
8 leiomyoma 30.3 KIT DES ACTC1
9 syringocystadenoma papilliferum 30.2 DES ACTC1
10 spindle cell lipoma 30.2 DES ACTC1
11 congenital fibrosarcoma 30.1 DES ACTC1
12 glomus tumor 30.1 DES ACTC1
13 carcinosarcoma 30.1 KIT DES ACTC1
14 spindle cell sarcoma 30.1 NF2 DES ACTC1
15 gastrointestinal stromal tumor 30.1 KIT DES ACTC1
16 biphasic synovial sarcoma 30.0 EWSR1 DES
17 angiolipoma 30.0 DES ACTC1
18 parachordoma 30.0 DES ACTC1
19 glomangioma 30.0 DES ACTC1
20 ossifying fibromyxoid tumor 30.0 DES ACTC1
21 malignant fibroxanthoma 30.0 DES ACTC1
22 angiomyolipoma 29.9 KIT DES ACTC1
23 hemangiopericytoma, malignant 29.9 DES ACTC1
24 adenosarcoma 29.9 KIT DES
25 fibromatosis 29.9 KIT DES ACTC1
26 follicular dendritic cell sarcoma 29.8 KIT FCER2 CR2
27 spindle cell liposarcoma 29.7 KIT CR2
28 malignant mesenchymoma 29.7 KIT EWSR1 DES
29 constipation 29.7 SST RET KIT
30 neurilemmoma 29.6 NF2 KIT DES
31 perivascular epithelioid cell tumor 29.6 KIT DES ACTC1
32 inflammatory myofibroblastic tumor 29.6 KIT DES CR2 ACTC1
33 embryonal sarcoma 29.5 KIT DES
34 muscle cancer 29.5 KIT EWSR1 DES
35 reticulum cell sarcoma 29.5 FCER2 DES CR2 ACTC1
36 endocrine gland cancer 29.5 SST RET MMP2
37 neurofibromatosis, type iv, of riccardi 29.4 RET NF2 KIT
38 chondromyxoid fibroma 29.2 DES ACTC1
39 smooth muscle tumor 29.2 KIT DES CR2 ACTC1
40 ewing sarcoma 29.0 MMP2 KIT EWSR1 DES
41 malignant peripheral nerve sheath tumor 28.9 NF2 KIT ACTC1
42 dendritic cell tumor 28.8 FSCN1 FCER2 CR2 ACTC1
43 rare tumor of pancreas 12.2
44 rare tumor of gallbladder and extrahepatic biliary tract 12.1
45 rare tumor of small intestine 12.1
46 rare tumor of intestine 12.1
47 non-rare tumor 12.1
48 rare tumor of neuroepithelial tissue 12.1
49 rare tumor of salivary glands 12.1
50 hepatocellular carcinoma 11.6

Graphical network of the top 20 diseases related to Rare Tumor:



Diseases related to Rare Tumor

Symptoms & Phenotypes for Rare Tumor

MGI Mouse Phenotypes related to Rare Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.96 ACTC1 CR2 DES FCER2 KIT LATS2
2 immune system MP:0005387 9.76 CR2 FCER2 FSCN1 KIT MMP2 NF2
3 mortality/aging MP:0010768 9.7 ACTC1 CR2 DES FCER2 FSCN1 KIT
4 muscle MP:0005369 9.1 ACTC1 DES KIT LATS2 MMP2 RET

Drugs & Therapeutics for Rare Tumor

Drugs for Rare Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 2, Phase 3 58-05-9 143 6006
2
Pemetrexed Approved, Investigational Phase 2, Phase 3 150399-23-8, 137281-23-3 60843 446556
3
Methylcobalamin Approved, Experimental, Investigational Phase 2, Phase 3 13422-55-4
4
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 15589840
5
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
6
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
7
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
8
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
9 Folic Acid Antagonists Phase 2, Phase 3
10 Vitamin B9 Phase 2, Phase 3
11 Folate Phase 2, Phase 3
12 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3
13 Vitamin B Complex Phase 2, Phase 3
14 Vitamins Phase 2, Phase 3
15 Vitamin B 12 Phase 2, Phase 3
16 Vitamin B12 Phase 2, Phase 3
17
Vincristine Approved, Investigational Phase 2 57-22-7, 2068-78-2 5978
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Mitotane Approved Phase 2 53-19-0 4211
20
Etoposide Approved Phase 2 33419-42-0 36462
21
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
22
Olaparib Approved Phase 2 763113-22-0 23725625
23
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616 46835353
25
Palbociclib Approved, Investigational Phase 2 571190-30-2 5330286 11431660 5005498
26
afatinib Approved Phase 2 439081-18-2, 850140-72-6 10184653
27
Vemurafenib Approved Phase 2 918504-65-1 42611257 23252090
28
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
29
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
30
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
31
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
32
Durvalumab Approved, Investigational Phase 2 1428935-60-7
33
Ifosfamide Approved Phase 2 3778-73-2 3690
34
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
35
Tamoxifen Approved Phase 2 10540-29-1 2733526
36
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
37
rituximab Approved Phase 2 174722-31-7 10201696
38
Gemcitabine Approved Phase 2 95058-81-4 60750
39
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
40
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
41
Salmon Calcitonin Approved, Investigational Phase 2 47931-85-1 16129616
42
Levodopa Approved Phase 2 59-92-7 6047
43
Imiquimod Approved, Investigational Phase 1, Phase 2 99011-02-6 57469
44
Tremelimumab Investigational Phase 2 745013-59-6
45
Calcitonin gene-related peptide Investigational Phase 2 83652-28-2
46 Antineoplastic Agents, Phytogenic Phase 2
47 Tubulin Modulators Phase 2
48 Antimitotic Agents Phase 2
49
Liposomal doxorubicin Phase 2 31703
50 Topoisomerase Inhibitors Phase 2

Interventional clinical trials:

(show all 41)
# Name Status NCT ID Phase Drugs
1 A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) Completed NCT00651456 Phase 2, Phase 3 Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
2 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
3 A Study of Combination Chemotherapy & Surgical Resection in the Tx of Adrenocortical Cancer: Mitotane & Continuous Infusion Doxorubicin, Vincristine & Etoposide w/the P-glycoprotein Antagonist, Tariquidar (XR9576), Before & After Surgical Resection Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
4 Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event Recruiting NCT03239015 Phase 2 Gefitinib;Erlotinib;Afatinib;Trastuzumab;Oxazolidine;Olaparib;Everolimus;Cabozantinib;Vemurafenib;Dabrafenib;Palbociclib
5 Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
6 A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors Recruiting NCT02938793 Phase 2 Durvalumab;Tremelimumab
7 Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP Recruiting NCT02817958 Phase 2 Chemotherapy TIP
8 Phase II Study of Hormone Therapy With Tamoxifen in Patients With Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression Recruiting NCT03870399 Phase 2 Tamoxifen
9 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study Active, not recruiting NCT02853370 Phase 2 Bendamustine and Rituximab
10 A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study Suspended NCT01627795 Phase 1, Phase 2 Oshadi D and Oshadi R
11 Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients Terminated NCT02472080 Phase 2 gemcitabine -oxaliplatine combination
12 Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy Terminated NCT01383746 Phase 1, Phase 2
13 Clinical Evaluation of 18F-DOPA Positron Emission Tomography in Medullary Thyroid Cancer. Terminated NCT00647140 Phase 2
14 Phase I/II Study of Peptide Vaccination Associated With Tumoral Immunomodulation With Proinflammatory Cytokines and Imiquimod in Patients With Advanced Metastatic Melanoma Terminated NCT01191034 Phase 1, Phase 2 Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
15 Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma Terminated NCT01723813 Phase 1, Phase 2
16 Phase I/II Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors Completed NCT00183833 Phase 1 capecitabine, imatinib mesylate
17 Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate in Patient With Rare Tumor (Phase I Study) Completed NCT01046487 Phase 1 Imatinib mesylate, Cyclophosphamide (Dosing level 1 );Imatinib mesylate, Cyclophosphamide (Dosing level 2);Imatinib mesylate, Cyclophosphamide (Dosing level 3)
18 A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide Recruiting NCT02573896 Phase 1 Ch14.18;Lenalidomide
19 A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma Terminated NCT01832974 Phase 1 IL-13-PE
20 Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma Unknown status NCT01594203
21 Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors Completed NCT02334930
22 Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma Completed NCT03178409
23 A Pilot Study of Combined Immunochemotherapy Followed by Reduced Dose RT for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00594815 Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine
24 Clinicopathological Importance of Colorectal Medullary Carcinoma: Retrospective Cohort Study Completed NCT03774862
25 Procurement of Blood and Tissue From Patients With Primary and Metastatic Alveolar Soft Part Sarcoma and Blood From Healthy Controls for In Vitro and In Vivo Model Development Completed NCT00340353
26 Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma Completed NCT02015026
27 Sentinel Lymph Node Biopsy in Porocarcinoma: A Case Reports Completed NCT03647631
28 Retrospective Study of Cases of Small Cell Lung Cancer (SCLC) That Appeared During Treatment of Another Lung Carcinoma With or Without Oncogenic Activation (TransCPC) Completed NCT03419286
29 Natural History Study of Children and Adults With Chordoma Recruiting NCT03910465
30 International Pediatric Adrenocortical Tumor Registry Recruiting NCT00700414
31 Natural History and Biospecimen Acquisition Study for Children and Adults With Rare Solid Tumors Recruiting NCT03739827
32 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158
33 Neuroblastoma Biology Studies Recruiting NCT00904241
34 DICER1-Related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study Recruiting NCT01247597
35 Clinico-biological Study/Characterization of Rhabdomyosarcoma in AYA (Adolescents and Young Adults, 15-25-year-old Patients) Recruiting NCT03462888
36 Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers Active, not recruiting NCT02162732
37 A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer Active, not recruiting NCT01802567
38 Family Study of Head and Neck Cancers in Taiwan Active, not recruiting NCT00342147
39 Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome Active, not recruiting NCT00565903
40 Rare Tumor Case Review Terminated NCT00229879
41 Topical Anesthesia to Decrease the Trigeminal-Cardiac Reflex During Intra-arterial Injection of Chemotherapy for Retinoblastoma in Children. Withdrawn NCT02955524 Early Phase 1 Tetracaine 0.5%;Lidocaine hydrochloride ophthalmic gel 3.5%

Search NIH Clinical Center for Rare Tumor

Genetic Tests for Rare Tumor

Anatomical Context for Rare Tumor

MalaCards organs/tissues related to Rare Tumor:

41
Breast, Pancreas, Liver, Thyroid, Lung, Bone, Kidney

Publications for Rare Tumor

Articles related to Rare Tumor:

(show top 50) (show all 9727)
# Title Authors PMID Year
1
Myoepithelioma of the soft tissue: A systematic review of clinical reports. 38
31085025 2019
2
68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma. 38
31270559 2019
3
Papillary Carcinoma of Stensen's Duct with Intestinal Differentiation. 38
29774486 2019
4
Schwannoma masquerading as adrenocortical tumor: A case report and review of literature. 38
31297325 2019
5
Suprasellar ganglioglioma presenting as a middle cerebral artery infarction. 38
31289852 2019
6
Collision of Subungual Neurofibroma and Onychomatricoma: S100 Positivity as a Clue. 38
30730391 2019
7
Adrenocortical carcinoma - towards genomics guided clinical care. 38
31147626 2019
8
Intracranial Extraskeletal Mesenchymal Chondrosarcoma: Case Report and Review of the Literature of Reported Cases in Adults and Children. 38
31158544 2019
9
Epstein-Barr Virus-Positive Large Cell Neuroendocrine Carcinoma of the Nasopharynx: Report of One Case and Review of the Literature. 38
30191506 2019
10
Primary, Dural-Based, Ewing Sarcoma Manifesting with Seizure Activity: Presentation of a Rare Tumor Entity with Literature Review. 38
31203070 2019
11
Phosphaturic Mesenchymal Tumor of Soft Tissue of the Foot: Report of a Case With Review of the Literature. 38
31261249 2019
12
18F-FDG PET/CT in Oral Cuniculatum Carcinoma. 38
31246683 2019
13
Human Papillomavirus-Related Multiphenotypic Sinonasal Carcinoma with Unique HPV type 52 Association: A Case Report with Review of Literature. 38
30259271 2019
14
Laryngeal reconstruction for recurrent desmoid tumor using three-dimensional modeling: A unique approach for a rare tumor. 38
30585331 2019
15
Incidental Finding of Gastric Schwannoma in a Renal Failure Patient - Managed by a Minimally Invasive Procedure: Report of a Rare Case. 38
31434865 2019
16
Genetic Changes of P53 and Kras in Gallbladder Carcinoma in Kumaon Region of Uttarakhand. 38
31396884 2019
17
What can independent research for mesothelioma achieve to treat this orphan disease? 38
31262194 2019
18
[Microcystic serous cystadenoma: An uncommon neoplasm of pancreas. Report of two cases]. 38
30711334 2019
19
True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndrome. 38
31044390 2019
20
Resection of a huge mediastinal well-differentiated liposarcoma involving left thoracic cavity. 38
31387607 2019
21
Fine-needle aspiration cytology of the apocrine variant of epithelial-myoepithelial carcinoma. 38
31433568 2019
22
Rare cancers in childhood and adolescence in Brazil: First report of data from 19 population-based cancer registries. 38
31013367 2019
23
An update on emerging drugs in osteosarcoma: towards tailored therapies? 38
31401903 2019
24
Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma in a Young Adult-Report of a Rare Case. 38
30994389 2019
25
Synthesis of novel benzothiazole amides: Evaluation of PPAR activity and anti-proliferative effects in paraganglioma, pancreatic and colorectal cancer cell lines. 38
31272790 2019
26
Esthesioneuroblastoma on 68Ga DOTANOC PET/CT. 38
31274630 2019
27
Clinicopathological features and survival for gallbladder NEN: A population-based study. 38
31398710 2019
28
Meningeal metastasis of a malignant peritoneal mesothelioma: A case report and literature review. 38
31411522 2019
29
Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. 38
30635447 2019
30
Precise Size-Based Cell Separation via the Coupling of Inertial Microfluidics and Deterministic Lateral Displacement. 38
31304740 2019
31
AYA testis cancer: The unmet challenge. 38
31066223 2019
32
Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients. 38
31305297 2019
33
Imaging and Surgical Treatment of Primary Pulmonary Artery Sarcoma. 38
30535656 2019
34
Clinico-pathological features of gynecological myopericytoma: a challenging diagnosis in an exceptional location. 38
31410559 2019
35
Gastric Perivascular Epithelioid Cell Tumor (PEComa). 38
31141597 2019
36
Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation. 38
31335448 2019
37
[18F]fluorodeoxyglucose-positron emission tomography and glucose-transporter type 1 (GLUT-1) expression in untreated primary small bowel adenocarcinoma. 38
31271267 2019
38
Gastric schwannoma with high accumulation on fluorodeoxyglucose-positron emission tomography resected by non-exposed endoscopic wall-inversion surgery. 38
31270750 2019
39
Cytological features of a renal angiomyolipoma in a child-A case report. 38
31293099 2019
40
Thyroid-Like Follicular Renal Cell Carcinoma Arising Within Benign Mixed Epithelial and Stromal Tumor. 38
31342803 2019
41
Primary adrenal schwannoma: a series of 31 cases emphasizing their clinicopathologic features and favorable prognosis. 38
31278687 2019
42
Simultaneous gastric adenosquamous carcinoma and gastric carcinoma with lymphoid stroma: A case report. 38
31289682 2019
43
Clinical silence of pulmonary lymphoepithelioma-like carcinoma with subcutaneous metastasis: a case report. 38
31340830 2019
44
Primary gastric choriocarcinoma - a rare and aggressive tumor with multilineage differentiation: A case report. 38
31417929 2019
45
[New system combining Hyams grading system and modified Kadish stage to evaluate the progress of esthesioneuroblastoma]. 38
31327194 2019
46
Prognosis and prognostic factors of esophageal spindle cell carcinoma treated by esophagectomy: a retrospective single-institution analysis. 38
30937574 2019
47
Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study 38
30873825 2019
48
Outcome of Metastatic and Recurrent Ovarian Dysgerminoma Using Radiation Therapy and Chemotherapy in a Dog. 38
31099610 2019
49
Diagnostic evaluation and treatment of primary breast osteosarcoma: A case report. 38
31077474 2019
50
Multimodality-imaging manifestations of primary renal-allograft synovial sarcoma: First case report and literature review. 38
31367627 2019

Variations for Rare Tumor

Expression for Rare Tumor

Search GEO for disease gene expression data for Rare Tumor.

Pathways for Rare Tumor

Pathways related to Rare Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.84 RET MMP2 KIT HLA-DRB1 FSCN1 FCER2
2 11.95 NF2 FSCN1 DES ACTC1
3 11.55 MMP2 FSCN1 FCER2
4 10.91 KIT HLA-DRB1 FCER2 CR2
5 10.86 KIT FCER2 CR2
6 10.83 NF2 LATS2

GO Terms for Rare Tumor

Cellular components related to Rare Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.91 RET NF2 MMP2 KIT HLA-DRB1 FCER2
2 receptor complex GO:0043235 9.5 RET KIT CR2
3 lamellipodium GO:0030027 9.33 NF2 FSCN1 ACTC1
4 cell-cell junction GO:0005911 9.13 KIT FSCN1 DES
5 filopodium GO:0030175 8.8 NF2 FSCN1 ACTC1

Biological processes related to Rare Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 8.92 MMP2 KIT FSCN1 FCER2

Sources for Rare Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....